Prostatype Genomics AB ("Prostatype Genomics" or the "Company") announces today the final outcome of the share issue with preferential rights for the Company's shareholders ("Preferential Share Issue") whose subscription period ended on 11 May 2023. The subscription summary shows that 77,226,496 shares, corresponding to approximately 56.3 percent of the Preferential Share Issue was subscribed with or without the support of subscription rights, of which 71,151,384 shares, corresponding to approximately 51.9 percent of the Preferential Share Issue, were subscribed with the support of subscription rights and 6,075,112 shares, corresponding to approximately 4.4 percent of the Preferential Share Issue, was subscribed without the support of subscription rights. The guarantors are thereby allocated approximately 13.7 percent of the Preferential Share Issue, whereby the Preferential Share Issue is subscribed to approximately 70 percent in total, and Prostatype Genomics is thus provided with approximately SEK 24.0 million before issue costs. Those who have been allocated shares without the support of subscription rights will shortly be notified by settlement note or alternatively via their trustee.
THIS PRESS RELEASE MAY NOT BE DISCLOSED, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY IN OR TO RUSSIA, BELARUS, AUSTRALIA, HONGKONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, USA, OR ANY OTHER JURISDICTION WHERE SUCH ACTION IS IN WHOLE OR IN PART FOR LEGAL RESTRICTIONS. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO ACQUIRE SECURITIES IN PROSTATYPE GENOMICS AB. SEE ALSO THE “IMPORTANT INFORMATION” SECTION BELOW.
The subscription period in the Preferential Share Issue ended on 11 May 2023 and the final outcome shows that the Preferential Share Issue was subscribed for approximately SEK 19.3 million with or without the support of subscription rights, corresponding to approximately 56.3 percent of the Preferential Share Issue, of which 71,151,384 shares, corresponding to approximately SEK 17.8 million or approximately 51.9 percent of the Preferential Share Issue, was subscribed with the support of subscription rights and 6,075,112 shares, corresponding to approximately SEK 1.5 million or approximately 4.4 percent of the Preferential Share Issue, were subscribed without the support of subscription rights. The guarantors are thereby allocated approximately 13.7 percent of the Preferential Share Issue. Prostatype Genomics will receive approximately SEK 24.0 million before deducting issue costs.
Allocation in the Preferential Share Issue
Those who have subscribed for shares without the support of subscription rights have been allocated shares in accordance with the principles stated in the prospectus published by the Company on 24 April 2023. Settlement notes are expected to be sent out around 16 May 2023. Subscribed and allocated shares must be paid in cash in accordance with the instructions on the statement. Trustee-registered shareholders will be notified of allocation in accordance with the trustee's procedures.
Dilution due to the Preferential Share Issue
After registration of the Preferential Share Issue with the Swedish Companies Registration Office, the Company's share capital will increase by approximately SEK 5,760,593.28 to a total of approximately SEK 7,132,320.42. The number of shares in the Company will increase by 96,009,888 to a total of 118,872,007. Shareholders who have not participated in the Preferential Share Issue have thus had their ownership stake in Prostatype Genomics diluted by approximately 80.8 percent.
Trading with paid subscribed shares
Trading with paid subscribed shares (sw. BTA) will take place on the Nasdaq First North Growth Market until the week after the Preferential Share Issue has been registered with the Swedish Companies Registration Office. Registration of the Preferential Share Issue is expected to take place during week 21, 2023.
“The support from existing shareholders, and from new investors, during these challenging times is gratifying and we look forward to keeping you updated on Prostatype Genomics' developments. We are at the beginning of our commercialization so the activity is high and especially our work for next year's launch in the USA will be a priority during the year along with continued launch work in Europe. With the financial contribution, we now have the conditions to continue these investments and we wish to express our sincere thanks to our shareholders", says Fredrik Persson, CEO Prostatype Genomics”.
Prostatype Genomics has appointed Erik Penser Bank AB and Lindahl law firm as financial and legal advisors respectively, in connection to the Preferential Share Issue.
For further information about Prostatype Genomics, please contact:
Nicklas Rosendal, Press Contact
Telefon: +46 708-89 33 34
About Prostatype Genomics AB
Prostatype® is a genetic test that is available to patients and treating urologists as a supplementary decision support tool to answer the question of radical treatment or no radical treatment of prostate cancer. The test is developed by a research group at Karolinska Institutet and is provided by Prostatype Genomics AB.
Svensk Kapitalmarknadsgranskning AB
The information in this press release neither contains nor constitutes an offer to acquire, subscribe or otherwise trade in shares, warrants or other securities in Prostatype Genomics. No action has been taken and no action will be taken to permit an offer to the public in any jurisdictions other than Sweden. The invitation to interested persons to subscribe for shares in Prostatype Genomics takes place solely through the prospectus that Prostatype Genomics published on 24 April 2023.
The information contained in this press release may not be disclosed, published or distributed, directly or indirectly, within or to the United States, Australia, Hongkong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa, Russia, Belarus or any other jurisdiction where such action would be illegal, subject to legal restrictions or require measures other than those that follow from Swedish law. Actions contrary to this instruction may constitute a violation of applicable securities legislation. No shares or other securities of Prostatype Genomics have been registered, and no shares or other securities will be registered, under the United States Securities Act of 1933 from time to time ("Securities Act") or the securities laws of any state or other jurisdiction of the United States and may not be offered, sold or otherwise transferred, directly or indirectly, in or to the United States, except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and pursuant to the securities laws of the relevant state or other jurisdiction in the United States. This communication is distributed to and directed solely to persons in the United Kingdom who are (i) professional investors falling within the scope of Article 19(5) of the U.K. from time to time in force; Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 ("the Order") or (ii) high net worth subjects and other persons to whom this notice may lawfully be addressed, who are subject to Article 49(2)(a)-(d) ) in the Order (all such persons are collectively referred to as "Relevant Persons"). Persons who are not Relevant Persons may not act on or rely on the information in this communication. An investment or investment measure referred to in this communication is only possible for Relevant Persons and will only be completed with Relevant Persons. Persons who disseminate this communication must themselves ensure that such dissemination is permitted.
This press release contains forward-looking statements that refer to the Company's intentions, assessments or expectations regarding the Company's future results, financial position, liquidity, development, prospects, expected growth, strategies and opportunities as well as the markets in which the Company operates. Forward-looking statements are statements that do not relate to historical facts and can be identified by the inclusion of expressions such as "believes", "expects", "anticipates", "intends", "estimates", "will", "may", "assumes", "should" "could" and, in each case, negations thereof, or similar expressions. The forward-looking statements in this press release are based on various assumptions, which in several cases are based on additional assumptions. Although the Company believes that the assumptions reflected in these forward-looking statements are reasonable, there can be no assurance that they will occur or that they are accurate. As these assumptions are based on assumptions or estimates and are subject to risks and uncertainties, the actual result or outcome may, for many different reasons, differ materially from what appears in the forward-looking statements.
Such risks, uncertainties, contingencies and other material factors may cause actual events to differ materially from the expectations expressed or implied in this press release through the forward-looking statements. The Company does not warrant that the assumptions underlying the forward-looking statements in this press release are correct and any reader of the press release should not place undue reliance on the forward-looking statements in this press release. The information, opinions and forward-looking statements expressed or implied herein are provided only as of the date of this press release and are subject to change. Neither the Company nor anyone else undertakes to revise, update, confirm or publicly announce any revision of any forward-looking statement to reflect events occurring or circumstances occurring with respect to the contents of this press release, except as required by law or Nasdaq First North Growth Markets' regulations for issuers.